

<b>Reference:</b>	FOI.8065.22
<b>Subject:</b>	Primary Care Rebates
<b>Date of Request:</b>	26 January 2022

**Requested:**

I would like to request the following information with regards to primary rebates schemes that have been signed by your CCG/ Board in the past 12 months.

1. Are there any signed for any of the following products, and if so, which ones:
  - Insulins (basal, bolus and premix)
  - GLP-1 (i.e Trulicity)
  - DPP-IV (i.e Januvia or Onglyza)
  - SGLT-2 (i.e Invokana)
  - Growth Hormones (norditropin; omnitrope; Genotropin; humatrope; nutropinAq; Saizen)
2. What are the start and finish dates (or ongoing if open ended)?
3. Which rebates are independent? or are they aligned to PrescQIPP?
4. What is the total number of primary rebate schemes (any included) that your CCG/ Board has signed?

**Response:**

1. Hywel Dda University Health Board (UHB) confirms that it did not sign rebate agreements for any of the listed products, during the previous twelve (12) months.
2. Not applicable.
3. The UHB confirms that all of its Primary Care Rebate Schemes are independent.
4. The UHB confirms that it has signed a total number of fifty-four (54) Primary Care Rebate Schemes.